Efficacy of Nasal Spray Hypertonic Puressentiel on Symptoms of Allergic Rhinitis
Overview
Prospective multicentric study. 60 subjects with allergic rhinitis will be enrolled to test the efficacy of nasal hypertonic spray Puressentiel on symptoms of allergic rhinitis and nasal peak flow. Subjects with allergic rhinitis and nasal obstruction will use during 30 days the nasal spray (2 nebulisations /day in each nostril) during 30 days. Rhinitis symptoms questionnaire and nasal inspiratory peak flow will be evaluated before and after 30 days of exposure.
Full Title of Study: “Evaluation of the Efficiency of Nasal Spray Hypertonic Puressentiel on Symptoms of Patients With Allergic Rhinitis”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
- Study Primary Completion Date: September 30, 2019
Detailed Description
Objective: evaluate the efficiency of a nasal hypertonic spray Puressentiel in subjects with allergic rhinitis and nasal obstruction. Inclusion criteria: subjects with allergic obstructive rhinitis without treatment or remaining symptomatic despite treatment. Duration of exposure: 2 nasal sprays per day (morning and evening) during 30 months. Primary criteria of efficacy: Rhinitis questionnaire. Secondary criteria: Inspiratory nasal peak flow
Interventions
- Other: nasal hypertonic spray: combination of hypertonic sea water and organic rosemary floral water with essential oils (ravintsara, geranium, eucalyptus radiata, niaouli)
- One spray of nasal hypertonic spray morning and evening every day during 30 days
Arms, Groups and Cohorts
- Experimental: allergic rhinitis
- administration of a nasal hypertonic spray twice a day for one month
Clinical Trial Outcome Measures
Primary Measures
- Rhinitis auto questionnaire symptoms
- Time Frame: Measurement at Day 0
- 5 questions quoted from 1 (worse) to 5 (best).
- Rhinitis auto questionnaire symptoms
- Time Frame: Measurement at Day 30
- 5 questions quoted from 1 (worse) to 5 (best).
Secondary Measures
- Nasal inspiratory peak flow
- Time Frame: Measurement at Day 0 and Day 30
- Inspiratory nasal peak flow
- Nasal inspiratory peak flow
- Time Frame: Measurement at Day 30
- Inspiratory nasal peak flow
Participating in This Clinical Trial
Inclusion Criteria
- allergic rhinitis with nasal obstruction Exclusion Criteria:
- pregnant patients – patients with severe asthma
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Puressentiel
- Collaborator
- University Hospital, Montpellier
- Provider of Information About this Clinical Study
- Sponsor
- Overall Contact(s)
- pascal Demoly, MD, PhD, 33675034090, pascal.demoly@inserm.fr
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.